Access, Cost, and Switching Questions Retatrutide availability and cost should not be compared with tirzepatide as if both were established market options everywhere
In previously reported Phase 2 clinical trial 2 (NCT06054698) results evaluating the 8 mg dose of HRS9531, participants taking HRS9531 achieved a mean weight loss of 23.6% (21.7% placebo-adjusted) I at week 36, with no plateau in weight loss and a favorable safety profile consistent with other GLP-1-based treatments
Rybelsus is not approved by the Food and Drug Administration (FDA) as a weight loss aid
Internal resistance is one of the key factors that can cause batteries to overheat or even explode
A smaller dose does not guarantee that side effects will be mild or temporary
Include sources such as lean red meat, pulses, dark green leafy vegetables, and fortified cereals